Monte Rosa Therapeutics, Inc. (GLUE)
$
18.5
-0.46 (-2.49%)
Key metrics
Financial statements
Free cash flow per share
1.7600
Market cap
1.2 Billion
Price to sales ratio
6.6365
Debt to equity
0.1634
Current ratio
6.5397
Income quality
7.1201
Average inventory
0
ROE
0.0828
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company engaged in the innovative development of small molecule precision medicines that utilize the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The net income ratio is -0.96 reflecting the company's profitability margin. Among its key products is an oral molecular glue degrader aimed at GSPT1, a translational termination factor that plays a significant role in Myc-driven cancers. Additionally, the company is advancing its work on CDK2 for treating ovarian, uterine, and breast cancers, as well as NEK7, which is being developed for inflammatory diseases, including Crohn's disease, neurodegenerative diseases, diabetes, and liver disease. The gross profit stands at $67,501,000.00 highlighting the company's profitability from core operations. Furthermore, Monte Rosa is focused on VAV1, a target protein linked to autoimmune diseases, and BCL11A, relevant in the treatment of hemoglobinopathies. The EBITDA ratio is -0.97 highlighting the company's operational efficiency, while depreciation and amortization expenses of $8,121,000.00 reflect the wear and tear of its assets. The company also incurred an income tax expense of $2,570,000.00 indicating its tax obligations. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts. With a market capitalization of $1,204,772,411.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. The stock is affordable at $6.33 suitable for budget-conscious investors. Additionally, the stock has a high average trading volume of 1,601,671.00 indicating strong liquidity, which may attract a wide range of investors. Belonging to the Healthcare sector, Monte Rosa is driving innovation and growth, serving as an important contributor to advancements in biopharmaceutical solutions. This positioning enhances the company's appeal as it continues to innovate in developing targeted therapies that leverage the body’s own biological processes for treating serious health conditions.
Is Monte Rosa Therapeutics, Inc. (GLUE) a good investment?
Investing in Monte Rosa Therapeutics, Inc. (GLUE) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Monte Rosa Therapeutics, Inc. (GLUE)'s stock forecast?
Analysts predict Monte Rosa Therapeutics, Inc. stock to fluctuate between $3.50 (low) and $25.77 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Monte Rosa Therapeutics, Inc.'s market capitalization?
As of 2026-02-12, Monte Rosa Therapeutics, Inc.'s market cap is $1,204,772,411, based on 65,122,833 outstanding shares.
How does Monte Rosa Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Monte Rosa Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Monte Rosa Therapeutics, Inc. (GLUE) stock?
To buy Monte Rosa Therapeutics, Inc. (GLUE) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for GLUE. Place an order (Market, Limit, etc.).
What is the best time to invest in Monte Rosa Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Monte Rosa Therapeutics, Inc. perform in the last earnings report?
Revenue: $75,622,000 | EPS: -$0.98 | Growth: -62.74%.
Where can I find Monte Rosa Therapeutics, Inc.'s investor relations reports?
Visit https://www.monterosatx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Monte Rosa Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Monte Rosa Therapeutics, Inc. stock?
All-time high: $45.56 (2021-09-07) | All-time low: $2.44 (2023-10-25).
What are the key trends affecting Monte Rosa Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc . (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price of $23.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant.
zacks.com
Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.
zacks.com
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
zacks.com
Monte Rosa Therapeutics (GLUE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
defenseworld.net
Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and NextCure (NASDAQ: NXTC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk. Volatility and Risk Monte Rosa Therapeutics has
zacks.com
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.29 per share a year ago.
seekingalpha.com
Monte Rosa Therapeutics shares jumped this week after the company expanded its collaboration with Novartis. The Novartis partnership brings significant upfront cash and external QuEEN platform validation. Monte Rosa's molecular glue degraders can target previously undruggable proteins.
zacks.com
Monte Rosa Therapeutics (GLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
zacks.com
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.43 per share a year ago.
globenewswire.com
BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreaking new discoveries featured on the cover of Science. The research article, “Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition,” details how Monte Rosa's proprietary artificial intelligence (AI) and machine learning (ML) engine has uncovered a broad range of human proteins potentially accessible to cereblon (CRBN)-based degradation, spanning diverse protein domains and classes.
See all news
